3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
5
Gastrointestinal
4
Head & Neck
3
Sarcoma
2
Thoracic
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Melanoma
6
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Skin Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Micrometastasis
1
Lymphatic Metastasis
1
Inflammatory Breast Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
40
Nivolumab
18
trametinib
13
Cyclophosphamide
13
dabrafenib
11
Vemurafenib
10
Interleukin-2
10
Ipilimumab
9
fludarabine
7
Docetaxel
7
fludarabine phosphate
6
cemiplimab
6
Paclitaxel
6
Cisplatin
6
Carboplatin
6
atezolizumab
5
Radiotherapy
5
Drug Therapy
5
Dacarbazine
5
Blood Specimen Collection
5
Biopsy
5
poly ICLC
4
binimetinib
4
Therapeutics
4
Psychiatric Rehabilitation
4
sotigalimab
3
montanide ISA 51
3
encorafenib
3
cobimetinib
3
budigalimab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Indocyanine Green
×
Dermatologic
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled